JP2024531437A5 - - Google Patents
Info
- Publication number
- JP2024531437A5 JP2024531437A5 JP2024510674A JP2024510674A JP2024531437A5 JP 2024531437 A5 JP2024531437 A5 JP 2024531437A5 JP 2024510674 A JP2024510674 A JP 2024510674A JP 2024510674 A JP2024510674 A JP 2024510674A JP 2024531437 A5 JP2024531437 A5 JP 2024531437A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- formula
- salt
- disorder
- mdma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163235460P | 2021-08-20 | 2021-08-20 | |
| US63/235,460 | 2021-08-20 | ||
| US202263298820P | 2022-01-12 | 2022-01-12 | |
| US63/298,820 | 2022-01-12 | ||
| PCT/CA2022/051269 WO2023019369A1 (en) | 2021-08-20 | 2022-08-22 | Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531437A JP2024531437A (ja) | 2024-08-29 |
| JP2024531437A5 true JP2024531437A5 (https=) | 2025-09-01 |
Family
ID=85239329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510674A Pending JP2024531437A (ja) | 2021-08-20 | 2022-08-22 | （ｒ）－３，４－メチレンジオキシメタンフェタミン及び（ｓ）－３，４－メチレンジオキシメタンフェタミン又は（ｒ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミン及び（ｓ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12053452B2 (https=) |
| EP (1) | EP4387612A4 (https=) |
| JP (1) | JP2024531437A (https=) |
| KR (1) | KR20240061644A (https=) |
| AU (1) | AU2022330718B2 (https=) |
| CA (1) | CA3229363A1 (https=) |
| IL (1) | IL310937A (https=) |
| WO (1) | WO2023019369A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022283967A1 (en) * | 2021-06-03 | 2024-01-18 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| KR20240165982A (ko) * | 2022-03-31 | 2024-11-25 | 트랜센드 테라퓨틱스 인코퍼레이티드 | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022150525A1 (en) * | 2021-01-06 | 2022-07-14 | Awakn Life Sciences | Mdma in the treatment of alcohol use disorder |
| WO2022235500A1 (en) | 2021-05-03 | 2022-11-10 | Mind Medicine, Inc. | Psychedelics for treatment of pain |
| JP2024517194A (ja) | 2021-05-03 | 2024-04-19 | マインド メディシン， インコーポレイテッド | サイケデリック薬の用量を漸増する方法 |
| US12611399B2 (en) | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| WO2022235514A1 (en) | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
| US20220354822A1 (en) * | 2021-05-05 | 2022-11-10 | Mind Medicine, Inc. | Mdma enantiomers |
| WO2022232948A1 (en) * | 2021-05-06 | 2022-11-10 | Pharmala Biotech Inc. | Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) |
| WO2022232949A1 (en) * | 2021-05-06 | 2022-11-10 | Pharmala Biotech Inc. | Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) |
| AU2022283967A1 (en) | 2021-06-03 | 2024-01-18 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| WO2023056472A1 (en) | 2021-09-30 | 2023-04-06 | ATAI Life Sciences AG | Enantiomeric ratios of 3,4-methylenedioxymethamphetamine and related metabolites and uses thereof |
| CA3242786A1 (en) | 2022-01-07 | 2023-07-13 | Universitatsspital Basel | R-mdma and s-mdma to assist psychotherapy |
-
2022
- 2022-08-22 AU AU2022330718A patent/AU2022330718B2/en active Active
- 2022-08-22 JP JP2024510674A patent/JP2024531437A/ja active Pending
- 2022-08-22 EP EP22857191.5A patent/EP4387612A4/en active Pending
- 2022-08-22 IL IL310937A patent/IL310937A/en unknown
- 2022-08-22 CA CA3229363A patent/CA3229363A1/en active Pending
- 2022-08-22 WO PCT/CA2022/051269 patent/WO2023019369A1/en not_active Ceased
- 2022-08-22 KR KR1020247009362A patent/KR20240061644A/ko active Pending
-
2023
- 2023-03-06 US US18/117,723 patent/US12053452B2/en active Active
-
2024
- 2024-06-19 US US18/747,519 patent/US20240335419A1/en active Pending
-
2025
- 2025-01-29 US US19/040,188 patent/US20250170095A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531437A5 (https=) | ||
| JP2023011027A (ja) | Ｒ－ケタミンおよびその塩の医薬品としての応用 | |
| JP2023530092A5 (https=) | ||
| JP4634008B2 (ja) | ２ｈ−ベンズイミダゾール−２−オン、１，３−ジヒドロ−１−（２−｛４−［３−（トリフルオロメチル）フェニル］−１−ピペラジニル｝エチル）−及びその生理学的に許容される酸付加塩の新規使用 | |
| JP2021519267A5 (https=) | ||
| JP2024516421A (ja) | Ｍｄｍａ鏡像異性体 | |
| JP7781768B2 (ja) | 神経学的および精神障害の治療方法 | |
| CZ302842B6 (cs) | Farmaceutický prostredek | |
| CN118576586A (zh) | 治疗神经和精神疾病的方法 | |
| JP2023508469A5 (https=) | ||
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| JP2011510014A5 (https=) | ||
| JP2005539068A5 (https=) | ||
| JP2012144545A (ja) | アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ | |
| JP2007505095A (ja) | うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ | |
| US20240065988A1 (en) | Combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders | |
| US20230181521A1 (en) | Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (mdai) | |
| US10647679B2 (en) | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto | |
| WO2023081899A1 (en) | Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof | |
| CN107835695A (zh) | 用于治疗自闭症的组合物和方法 | |
| CN113710319A (zh) | 用于治疗焦虑相关病症的组合物和方法 | |
| JP2007527905A (ja) | アルファ−２−デルタリガンドを含む組合せ | |
| JP2025501411A5 (https=) | ||
| JP2025501410A5 (https=) | ||
| CN1407890A (zh) | 牛皮癣的治疗 |